VCEL Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

90.76M

+20.41%

0.386

+1.58%

63.70M

+21.11%

-0.077

-66.3%

74.34M

+17.56%

0.092

-1025%

Estimates Revision

The market is revising Downward the revenue expectations for Vericel Corporation (VCEL) for FY2025, with the revenue forecasts being adjusted by -0.42% over the past three months. During the same period, the stock price has changed by 21.07%.

Revenue Estimates for FY2025

Revise Downward

-0.42%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+44.44%

In Past 3 Month

Stock Price

Go Up

+21.07%

In Past 3 Month

7 Analyst Rating

Wall Street analysts forecast VCEL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VCEL is 54.20 USD with a low forecast of 48.00 USD and a high forecast of 60.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

5 Buy

2 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

48.00

Averages

54.20

High

60.00

Current: 0.000

Low

48.00

Averages

54.20

High

60.00

Truist

Richard Newitter

Buy

downgrade

$50 -> $45

2025-12-18

Reason

Truist

Richard Newitter

Price Target

$50 -> $45

2025-12-18

downgrade

Buy

Reason

Truist analyst Richard Newitter lowered the firm's price target on Vericel to $45 from $50 and keeps a Buy rating on the shares as part of a broader research note previewing 2026 for MedTech. The firm is more positive on the industry heading into next year given a more attractive relative sector valuation, though it also sees the possibility of it being a "source" vs. a destination of new healthcare investment flows, the analyst tells investors in a research note. Truist adds it prefers names with 2026 catalysts fueling durable revenue acceleration or out-of-favor near-term narratives.

Truist

Richard Newitter

Buy

maintain

$41 -> $50

2025-11-07

Reason

Truist

Richard Newitter

Price Target

$41 -> $50

2025-11-07

maintain

Buy

Reason

Truist analyst Richard Newitter raised the firm's price target on Vericel to $50 from $41 and keeps a Buy rating on the shares. The firm notes Q3 saw a $3M revenue beat as both MACI & Burn Care outperformed, and importantly MACI delivered year-over-year acceleration on the heels of ramping MACI arthro adoption. The Q3 MACI beat should help alleviate anxiety around the steep implied Q4 revenue ramp to achieve gdce, which was reiterated, Truist adds.

Truist

Buy

downgrade

$46 -> $41

2025-10-15

Reason

Truist

Price Target

$46 -> $41

2025-10-15

downgrade

Buy

Reason

Truist lowered the firm's price target on Vericel to $41 from $46 and keeps a Buy rating on the shares as part of a broader research note previewing Q3 results in MedTech. The firm expects "healthy" Q3 revenue and earnings across its coverage but also braces for "stock volatility", with new money feeling notably absent from the space, the analyst tells investors in a research note. Similar to Q2, specialist and fund positioning could be poised to drive excessive reactions on anything counter to crowded positioning, Truist states, adding that it is more inclined to be positive on "cleaner" names where there is less perceived controversy heading into the quarter.

BTIG

Buy -> Neutral

downgrade

2025-09-17

Reason

BTIG

Price Target

2025-09-17

downgrade

Buy -> Neutral

Reason

BTIG downgraded Vericel to Neutral from Buy without a price target. The stock is down 42% this year following two \"softer\" quarters, the analyst tells investors in a research note. BTIG's survey of MACI users suggests limited increases in both biopsy growth and conversion from the MACI Arthro launch to drive estimates higher. The firm points out that 60% of surgeons surveyed expect no change to MACI volumes despite Arthro as an option now.

Canaccord

Buy

downgrade

$61 -> $58

2025-08-01

Reason

Canaccord

Price Target

$61 -> $58

2025-08-01

downgrade

Buy

Reason

Canaccord lowered the firm's price target on Vericel to $58 from $61 and keeps a Buy rating on the shares. The firm said they posted a solid quarter, beating bottom-line metrics but slightly missing MACI expectations while Epicel generated lower revenue than anticipated, even with the highest number of Epicel biopsies in a Q since 2023.

BTIG

Buy

downgrade

$58 -> $51

2025-07-14

Reason

BTIG

Price Target

$58 -> $51

2025-07-14

downgrade

Buy

Reason

BTIG lowered the firm's price target on Vericel to $51 from $58 and keeps a Buy rating on the shares as part of a broader research note previewing Q2 results in MedTech. Healthcare was a laggard in Q2 relative to the S&P, and early into Q3, MedTech is underperforming as fears of Medicaid cuts and hospital closures weigh on the sector following recent legislation, the analyst tells investors in a research note. The fears are likely overblown, though the earnings season is likely to offer a mixed picture as sentiment is extremely binary right now, with some companies pushing extreme valuations and others "left for dead", BTIG notes. The firm adds however that on one hand, inflation is calm, markets are at highs, and Fx has turned demonstrably favorable.

Valuation Metrics

The current forward P/E ratio for Vericel Corp (VCEL.O) is 68.35, compared to its 5-year average forward P/E of -53.81. For a more detailed relative valuation and DCF analysis to assess Vericel Corp 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-53.81

Current PE

68.35

Overvalued PE

587.94

Undervalued PE

-695.56

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

5Y Average EV/EBITDA

42.37

Current EV/EBITDA

21.49

Overvalued EV/EBITDA

58.11

Undervalued EV/EBITDA

26.63

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

8.88

Current PS

5.88

Overvalued PS

11.57

Undervalued PS

6.19

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders areSelling! The selling amount has increased 113.61% over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders areSelling! The selling amount has increased 113.61% over the last month.

Sold

Bought

VCEL News & Events

Events Timeline

No data

News

2.0

01-06NASDAQ.COM

VCEL Stock Shows Significant Volatility with 52-Week High of $63

8.0

2025-12-26NASDAQ.COM

American Express and Snowflake See Significant Options Trading Volume Surge

8.0

2025-12-19NASDAQ.COM

Inaugural Week of VCEL Options Trading for February 2026

People Also Watch

Frequently Asked Questions

What is Vericel Corp (VCEL) stock price today?

The current price of VCEL is 38.56 USD — it has decreased -5.33 % in the last trading day.

What is Vericel Corp (VCEL)'s business?

Vericel Corporation is a fully-integrated, commercial-stage biopharmaceutical company. The Company is a provider of advanced therapies for the sports medicine and severe burn care markets. It markets three products in the United States. MACI (autologous cultured chondrocytes on porcine collagen membrane) is an autologous-cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full-thickness burns greater than or equal to 30% of total body surface area. The Company also holds a license for North American rights to NexoBrid (anacaulase-bcdb), a biological orphan product containing proteolytic enzymes, which is indicated for the removal of eschar in adult and pediatric patients with deep partial thickness and/or full-thickness thermal burns.

What is the price predicton of VCEL Stock?

What is Vericel Corp (VCEL)'s revenue for the last quarter?

Vericel Corp revenue for the last quarter amounts to 67.50M USD, increased 16.58 % YoY.

What is Vericel Corp (VCEL)'s earnings per share (EPS) for the last quarter?

Vericel Corp. EPS for the last quarter amounts to 0.10 USD, decreased -600.00 % YoY.

What changes have occurred in the market's expectations for Vericel Corp (VCEL)'s fundamentals?

How many employees does Vericel Corp (VCEL). have?

Vericel Corp (VCEL) has 357 emplpoyees as of January 11 2026.

What is Vericel Corp (VCEL) market cap?

Today VCEL has the market capitalization of 1.95B USD.